FDA Approval Is Not an Investment Opportunity — Real Profit Potential Lies Elsewhere

Xenix Medical’s Riva posterior fixation system has received FDA approval for spinal fixation and stabilization; however, as a private company, its shares are not available for public investment, and investors cannot purchase stock or receive dividends.

Spinal Device Market byMedtronic, Zimmer Biomet, NuVasive, and Stryker. FDA approval is not the correct metric for assessing investment value; approval does not imply that a company has pricing power, distribution scale, or a path to profitability.

Medtronic is a pillar in the field of spinal devices, paying a quarterly dividend of $0.71 per share with a dividend yield of approximately 3.73%, and has increased its dividend for 47 consecutive years; Stryker exited the spinal business to focus on orthopedics and other areas, pays a quarterly dividend of $0.88 per share with a yield of about 1%, has raised its dividend for 19 consecutive years, generates revenue exceeding $25 billion, and maintains an operating margin of 19.5%.

Companies can be screened based on their ability to raise prices without losing customers; Medtronic and Stryker passed the test, while Xenix could not address the issue of pricing power due to the absence of financial data and other reasons.

When constructing an investment portfolio, one should select companies with pricing power, transparent balance sheets, and a history of paying dividends. There are compelling reasons to hold shares in established medical device companies, as compound interest can outpace inflation. Investors should not chase press releases but instead maintain long-term holdings in the underlying businesses.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express